lets_talk_prostate_cancer

The Covid-19 pandemic has had a significant impact for prostate cancer patients, who have been disproportionately impacted by the virus.

The pandemic has had a severely damaging effect on the prostate cancer patient pathway, including delays in patients seeking help or achieving an accurate diagnosis, and delays in accessing treatment and healthcare support in a timely way.

A new paper from the Let’s Talk Prostate Cancer campaign calls on policymakers to hear the voice of prostate cancer patients as they work to bring healthcare systems and services back to normal in the coming months. This includes ensuring increased provision for primary care services and support for healthcare workers, increased use of telemedicine and e-consultations and adoption of other digital technologies which can support patients receive the care and support they need during the pandemic.

The Let’s Talk Prostate Cancer campaign is organised and funded by Astellas Pharma Europe Ltd. The Campaign is comprised of an Expert Group of clinical and patient group representatives from across Europe. The objective of the campaign is to drive prostate cancer up the political and policy agenda and raise awareness of the unmet needs of people living with advanced prostate cancer.

Eiji Nakane, Vice-President, Strategic Operations & Communications said: “Prostate cancer patients have been one of the groups most heavily impacted by Covid-19, so we need to do everything we can to ensure patients receive the care and support they need, at the right time. This paper from the Let’s Talk Prostate Cancer Expert Group provides an analysis of the ways in which prostate cancer patients have been affected, and practical solutions for healthcare systems to adapt so they can continue to offer patients optimal treatment and care as soon as possible.”

Download the paper HERE

 

ONC_2020_0156_APE

 

The Astellas EST-C Communications team
will respond to emails from journalists.
For general media enquiries,
please email [email protected].